Active, not recruitingPhase 3NCT04042402
Long Term Extension Study in Patients With Primary Hyperoxaluria
Studying Primary hyperoxaluria type 1
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
- Principal Investigator
- Verity Rawson, MB.CHBDicerna, A Novo Nordisk Company
- Intervention
- DCR-PHXC(drug)
- Enrollment
- 75 enrolled
- Eligibility
- All sexes
- Timeline
- 2019 – 2030
Study locations (20)
- Clinical Research Site, San Francisco, California, United States
- Clinical Trial Site, Boston, Massachusetts, United States
- Clinical Trial Site, Rochester, Minnesota, United States
- Clinical Trial Site, New York, New York, United States
- Clinical Research Site, Herston, Queensland, Australia
- Clinical Trial Site, Melbourne, Australia
- Clinical Research Site, Hamilton, Ontario, Canada
- Clinical Trial Site, Bron, France
- Clinical Trial Site, Paris, France
- Clinical Trial Site, Bonn, Germany
- Clinical Trial Site, Heidelberg, Germany
- Clinical Research Site, Roma, Italy
- Clinical Trial Site, Fukuoka, Japan
- Clinical Trial Site, Nagoya, Japan
- Clinical Trial Site, Tokyo, Japan
- +5 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04042402 on ClinicalTrials.gov